Day: September 6, 2018

Clinithink receives RARE Champion of Hope award for their ‘notable efforts’ in rare disease

From Startup Clinithink Link to Full Article: https://clinithink.com/clinithink-receives-rare-champion-of-hope-award-for-their-notable-efforts-in-rare-disease/ Clinithink has been selected to receive the RARE Champion of Hope – Collaborations in Science and Technology award at the 7th Annual RARE Patient Advocacy Summit on October 4th in Irvine, California.   Over 200 individuals and organizations worldwide were nominated by

Cross-Industry Collaboration of GNS Healthcare, Amgen and Alliance for Clinical Trials in Oncology to Leverage AI to Advance Understanding of Treatment Response in Metastatic Colorectal Cancer

From Startup GNS Healthcare Link to Full Article: http://www.gnshealthcare.com/news/ai-collaboration-gns-amgen-alliance-colorectal-cancer/ Boris Hayete Senior Director, Precision Medicine     Q:  What is your role at GNS? A: I run the Precision Medicine team at GNS.  In this role, I am responsible for overseeing the scientific work of the team on a variety

Anika Appoints Dr. Cheryl Blanchard to Its Board of Directors

From Startup Anika Therapeutics Link to Full Article: http://ir.anikatherapeutics.com/news-releases/news-release-details/anika-appoints-dr-cheryl-blanchard-its-board-directors BEDFORD, Mass.–(BUSINESS WIRE)–Sep. 5, 2018– Anika Therapeutics, Inc. (NASDAQ: ANIK) (“Anika” or the “Company”), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced that Cheryl R. Blanchard, Ph.D., President

Anika to Participate in the 2018 Morgan Stanley Global Healthcare Conference on September 12, 2018

From Startup Anika Therapeutics Link to Full Article: http://ir.anikatherapeutics.com/news-releases/news-release-details/anika-participate-2018-morgan-stanley-global-healthcare BEDFORD, Mass.–(BUSINESS WIRE)–Sep. 5, 2018– Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced that its President and Chief Executive Officer, Joseph Darling, and

BrainStorm Cell Therapeutics Announces New Presentation Time at the H.C. Wainwright & Co. 20th Annual Investor Conference

From Startup Brainstorm Cell Therapeutics Link to Full Article: http://ir.brainstorm-cell.com/phoenix.zhtml?c=142287&p=irol-newsArticle&ID=2366181 Presentation and Live Webcast on Thursday, September 6th, 2.10pm ET NEW YORK and PETACH TIKVAH, Israel, Sept. 05, 2018 (GLOBE NEWSWIRE) — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced